gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE American · AIMHealthcareBiotechnology

AIM ImmunoTech Inc. (AIM)

$0.1521−5.53%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$0.15▼ 91.49% in range
Nov 5, 2025Low $0.15 · High $1.79Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

AIM ImmunoTech closed at $0.15 on Nov 5, down 5.53%, within 0.0% of its 52-week closing low. Volume of 993.8K shares was 2.24× its 20-day average (well above normal).

Split-adjusted performance: -16.8% over one month, -72.8% over six months, -90.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $26K, up 4.0% from a year earlier, with a net margin of -26876.9%.

Short interest was 1.1M shares at the Oct 15 settlement, down 23.3% from the prior report (3.6% of float, 1.5 days to cover).

Market cap$6.1M39.9M shares
Revenue · quarter$26.0K+4.0% YoY
Diluted EPS$-0.43—
P/E · TTM—P/S 63.9×
Net margin-26,876.9%Gross 80.8%
Dividend yieldNone
52-week range0.15 – 1.79−91.5% from high
Volume993.8K2.24× 20-day avg
Volatility · 60d68.6%Annualised
Short % of float3.6%1.5 days to cover
Net cash$6.3MCash $10.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −5.5%1M −16.8%3M −46.7%6M −72.8%YTD −86.5%1Y −90.5%3Y −67.0%5Y −91.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum11
Revenue growth47
Net margin4
Value (low P/E)—
Size6

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →
Shares short1.1M−23.3% vs prior
Days to cover1.5Settled Oct 15
% of float3.6%
Short vol. 10d31.5%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AIMAIM ImmunoTech$0.1521−5.53%−72.8%+4.0%−26876.9%—$6.1M
SNTISenti Biosciences Holdings$0.1645−6.85%−83.3%—−75000.0%—$6.3MCompare
CELZCreative Medical Technology Holdings$0.6059−7.05%−73.5%———$4.6MCompare
INABIN8bio$0.8300−10.82%−48.1%———$8.2MCompare
PMCBPharmaCyte Biotech$0.3752−1.52%−53.1%———$4.0MCompare
INTSIntensity Therapeutics$3.10−11.43%−39.3%———$10.1MCompare
LIMNLiminatus Pharma$2.63−5.88%−73.8%———$3.5MCompare
PASGPassage Bio$3.46−1.42%−15.2%———$11.1MCompare
SCLXScilex Holding$1.70−7.10%−78.9%−22.8%−1501.3%—$12.0MCompare

News about AIM ImmunoTech

All news →
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041GlobeNewswire Inc. · Sep 2, 2026▲ PositiveAIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private PlacementGlobeNewswire Inc. · May 20, 2026NeutralAIM ImmunoTech Provides Routine Update on Annual FilingsGlobeNewswire Inc. · Apr 13, 2026▼ NegativeWhy Is AIM ImmunoTech Stock Gaining Today?Benzinga · Mar 18, 2026▲ PositiveAIM ImmunoTech Announces Closing of its Rights OfferingGlobeNewswire Inc. · Mar 7, 2026Neutral

Quick answers

What does AIM ImmunoTech do?
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa).
What is AIM's market cap?
$6.07M, based on the Nov 5 close of $0.15.
Does AIM ImmunoTech pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AIM is sold short?
1.1M shares, 3.6% of float, as of Oct 15, 2026.
What sector is AIM in?
Healthcare, in the Biotechnology industry.

About AIM ImmunoTech

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

HQ: Ocala, FL21 employeesListed Nov 2, 1995aimimmuno.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology